ID | 1136 |
Name of the vaccine | Quadri Meningo |
Microbe | Bacteria |
Disease name | Meningococcal disease |
Name of bacteria | Neisseria meningitidis |
Type of vaccine | Polysaccharide |
Nucleic acid content | DNA |
Age | Over 2 years |
Description of the vaccine | Meningococcal polysaccharide vaccine (Group A, C, Y & W135) |
Name of the manufacturer | Biomed Labs |
Name of the manufacturing country | India |
Year of manufacture | NA |
Clinical Phase status | Approved |
Bacterial strain | Gram-negative diplococcus. |
Efficacy | NA |
Vaccine formulation | Single dose vial with syringe |
Dosage | Single dose (0.5 mL). |
Mechanism of action | Elicits bactericidal antibody response. Immunity lasts for three years. |
Route of administration | Subcutaneous |
Indications | Hajj and Umrah pilgrims heading to Mecca, Saudi Arabia, travellers heading to disease prone areas, military recruits and children and adults exposed to infected patients. |
Export | NA |
Approval | NA |
Adjuvant | NA |
Repurposing | For cerebrospinal meningitis |
Side effects of vaccine | Pain ,redness ,transient hyperthermia , headache and vomiting. |
Post vaccination | NA |
Dose type | Single dose |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | http://www.biomed.co.in/quadri-meningo/ |
Other name | NA |
Additional Links | NA
|